These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19427768)

  • 21. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperglycemia and cardiovascular risk: lessons from randomized trials].
    Grimaldi A
    Rev Prat; 2010 Apr; 60(4):464-8. PubMed ID: 20465116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
    Hopper I; Billah B; Skiba M; Krum H
    Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    J Am Coll Cardiol; 2009 Jan; 53(3):298-304. PubMed ID: 19147051
    [No Abstract]   [Full Text] [Related]  

  • 32. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis.
    Chen YH; Feng B; Chen ZW
    Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):116-20. PubMed ID: 22187291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents.
    Anselmino M
    J Diabetes Complications; 2009; 23(6):427-33. PubMed ID: 18768334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is an intensive glycaemic control beneficial in diabetes type 2?].
    Martin S
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1940. PubMed ID: 21948602
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
    Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.
    Sun F; Yu K; Wu S; Zhang Y; Yang Z; Shi L; Ji L; Zhan S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):386-95. PubMed ID: 23020934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antihyperglycaemic treatment and vascular diseases].
    Svacina S
    Vnitr Lek; 2010 Apr; 56(4):313-6. PubMed ID: 20465102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.